company background image
A207940 logo

Samsung BiologicsLtd KOSE:A207940 Stock Report

Last Price

₩753.00k

Market Cap

₩53.5t

7D

-4.7%

1Y

-3.1%

Updated

27 May, 2024

Data

Company Financials +

Samsung Biologics Co.,Ltd.

KOSE:A207940 Stock Report

Market Cap: ₩53.5t

A207940 Stock Overview

Engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally.

A207940 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Samsung Biologics Co.,Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Samsung BiologicsLtd
Historical stock prices
Current Share Price₩753,000.00
52 Week High₩880,000.00
52 Week Low₩668,000.00
Beta0.51
1 Month Change-2.21%
3 Month Change-6.69%
1 Year Change-3.09%
3 Year Change-10.89%
5 Year Change150.58%
Change since IPO422.92%

Recent News & Updates

Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

May 27
Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You

Apr 14
What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You

Recent updates

Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

May 27
Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You

Apr 14
What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You

With EPS Growth And More, Samsung BiologicsLtd (KRX:207940) Is Interesting

Mar 01
With EPS Growth And More, Samsung BiologicsLtd (KRX:207940) Is Interesting

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Jan 18
These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

What Kind Of Shareholders Own Samsung Biologics Co.,Ltd. (KRX:207940)?

Dec 28
What Kind Of Shareholders Own Samsung Biologics Co.,Ltd. (KRX:207940)?

How Much Is Samsung Biologics Co.,Ltd. (KRX:207940) CEO Getting Paid?

Dec 08
How Much Is Samsung Biologics Co.,Ltd. (KRX:207940) CEO Getting Paid?

Did You Miss Samsung BiologicsLtd's (KRX:207940) Impressive 112% Share Price Gain?

Nov 18
Did You Miss Samsung BiologicsLtd's (KRX:207940) Impressive 112% Share Price Gain?

Shareholder Returns

A207940KR Life SciencesKR Market
7D-4.7%-4.2%-1.4%
1Y-3.1%-1.0%4.3%

Return vs Industry: A207940 underperformed the KR Life Sciences industry which returned -1% over the past year.

Return vs Market: A207940 underperformed the KR Market which returned 4.3% over the past year.

Price Volatility

Is A207940's price volatile compared to industry and market?
A207940 volatility
A207940 Average Weekly Movement3.3%
Life Sciences Industry Average Movement6.1%
Market Average Movement5.0%
10% most volatile stocks in KR Market11.4%
10% least volatile stocks in KR Market2.3%

Stable Share Price: A207940 has not had significant price volatility in the past 3 months.

Volatility Over Time: A207940's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20114,284John Chongbo Rimsamsungbiologics.com

Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization.

Samsung Biologics Co.,Ltd. Fundamentals Summary

How do Samsung BiologicsLtd's earnings and revenue compare to its market cap?
A207940 fundamental statistics
Market cap₩53.45t
Earnings (TTM)₩895.30b
Revenue (TTM)₩3.92t

59.9x

P/E Ratio

13.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A207940 income statement (TTM)
Revenue₩3.92t
Cost of Revenue₩2.05t
Gross Profit₩1.87t
Other Expenses₩976.64b
Earnings₩895.30b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)12.58k
Gross Margin47.75%
Net Profit Margin22.84%
Debt/Equity Ratio15.0%

How did A207940 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.